SCHEMBL1835772

SCHEMBL1835772

CCc1ccccc1OC(N)=O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MAPT P10636 2/20 0.47
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 2/20 0.41
ATM Q13315 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GABRA1 P14867 1/20 0.40
GABRB2 P47870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30185875 1.00 L3MBTL1 (0.47) L3MBTL1NPSR1MAPTTHRATHRB
SCHEMBL1839407 0.87 THRA (0.50) NPSR1MAPTTHRATHRBMEN1
SCHEMBL30409585 0.87 THRA (0.50) NPSR1MAPTTHRATHRBMEN1
SCHEMBL11174975 0.86 MEN1 (0.42) L3MBTL1NPSR1THRATHRBTSHR
SCHEMBL21551503 0.85 L3MBTL1 (0.44) L3MBTL1NPSR1MAPTTHRATHRB
SCHEMBL4787649 0.84 EPHX1 (0.50) L3MBTL1NPSR1THRATHRBTSHR
SCHEMBL27471665 0.84 MEN1 (0.41) L3MBTL1NPSR1THRATHRBTSHR
SCHEMBL530112 0.84 THRA (0.58) MAPTTHRATHRBMEN1KMT2A
SCHEMBL29859888 0.84 THRA (0.58) MAPTTHRATHRBMEN1KMT2A
SCHEMBL47950 0.83 L3MBTL1 (0.50) L3MBTL1NPSR1MAPTTHRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4162362-A CONDESATION OF N-ARYL CARBAMIC ACID ESTER WITH FORMALDEHYDE IN THE PRESENCE OF A SULFONIC ACID ATLANTIC RICHFIELD COMPANY (US) 1979-07-24 US claimed
EP-3795561-B1 METHOD FOR PRODUCING CARBAMATE AND METHOD FOR PRODUCING ISOCYANATE ASAHI CHEMICAL IND (JP) 2024-11-06 EP disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
CN-118307529-A 2, 3-Dihydronaphthalene-embedded m-diazabenzene compound, synthesis method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2024-07-09 CN disclosed
CN-118215651-A Method for producing isocyanate compound, method for producing urethane compound, method for recovering amine compound, and isocyanate composition 旭化成株式会社 2024-06-18 CN disclosed
CN-114736219-B Antitumor compounds 法马马有限公司 2024-06-07 CN disclosed
CN-114751920-B Antitumor compounds 法马马有限公司 2024-06-07 CN disclosed
CN-118055926-A ROCK2 inhibitors and uses thereof 哈佛大学的校长及成员们 2024-05-17 CN disclosed
CN-113896685-B Indoleamine-2, 3-dioxygenase (IDO) inhibitors 益方生物科技(上海)股份有限公司 2024-02-06 CN disclosed
CN-103108642-A RNA interference in cutaneous and fibrotic conditions RXI PHARMACEUTICALS CORP 2013-05-15 CN disclosed
US-20110133121-A1 N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-06-09 US disclosed
EP-2322504-A1 PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER Asahi Kasei Chemicals Corporation (JP) 2011-05-18 EP disclosed
CN-101563089-A Boronic acids and esters as inhibitors of fatty amide hydrolase INFINITY DISCOVERY INC (US) 2009-10-21 CN disclosed
EP-1608365-A1 METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE Sucampo AG (CH) 2005-12-28 EP disclosed
WO-2004087138-A1 METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE SUCAMPO AG (CH) 2004-10-14 WO disclosed
US-4226883-A Carbamate derivatives and method for manufacture thereof YAMAMOTO IZURU 1980-10-07 US disclosed
US-4202986-A Preparation of diphenylmethane dicarbamates and polymethylene polyphenyl carbamates with Lewis acid catalysts intercalated in graphite ATLANTIC RICHFIELD COMPANY (US) 1980-05-13 US disclosed
US-4146727-A ACID CATALYSTS ATLANTIC RICHFIELD COMPANY (US) 1979-03-27 US disclosed
US-4130633-A Removal of selenium from urethane solutions ATLANTIC RICHFIELD COMPANY (US) 1978-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110133121-A1 N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound CPS1, ALKBH3, RCC1 L3MBTL1 4813/4885NPSR1 3821/4885MAPT 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.